Experimental Antitumor Activity of Platinum Coordination Complexes
The search for a “second-generation” Pt compound to supersede cisplatin has been conducted in many laboratories (1–13). For the past six years, the efforts at Bristol-Myers have been focused on finding analogs with improved antitumor activities and reduced toxicities relative to cisplatin as judged by their effects in animal models (1, 10, 11). The present discussion will be limited to a review of antitumor test results obtained with those Pt compounds now undergoing clinical evaluation, and a few other analogs of potential interest.
KeywordsAntitumor Activity L1210 Leukemia Normal Bone Marrow Cell Primary Screen Test Improve Antitumor Activity
Unable to display preview. Download preview PDF.
- 1.Bradner WT, Rose WC, Huftalen JB. 1980. Antitumor activity of platinum analogs. In Cisplatin: Current Status and New Developments (Prestayko AW, Croke ST, and Carter SK, eds.), Academic Press, Inc., New York, pp. 171–182.Google Scholar
- 4.Connors TA, Cleare MJ, Harrap KR. 1979. Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat. 63:1499–1502.Google Scholar
- 8.Meishen SJ, Gale GR, Lake LM, Frangakis CJ, Rosenblum MG, Walker Jr., EM, Atkins LM, Smith AB. 1976. Antileukemic properties of organoplatinum complexes. J. Natl. Cancer Inst. 57:841–845.Google Scholar
- 13.Wolpert-DeFillippes MK. 1980. Antitumor activity of cisplatin analogs.In Cisplatin: Current Status and New Developments (Prestayko AW, Crooke ST and Carter SK, eds.), Academic Press, Inc., New York, pp 183–191.Google Scholar